Radiotherapy quality assurance in the PROTECT trial – a European randomised phase III-trial comparing proton and photon therapy in the treatment of patients with oesophageal cancer

A comprehensive RTQA programme was implemented for the PROTECT phase III trial. All centres adhered to guidelines for pre-trial QA. For on-trial QA, major variations were primarily seen for target delineations (< 30%), and no treatment plans required re-optimisation.

Authors

Institutions

Publication Details

Journal
Acta Oncologica
Published
2025-03-13
DOI
https://doi.org/10.2340/1651-226x.2025.42774
Citations
4
Primary Topic
Advanced Radiotherapy Techniques
Type
article
Field-Weighted Citation Impact
7.53
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Radiotherapy quality assurance in the PROTECT trial – a European randomised phase III-trial comparing proton and photon therapy in the treatment of patients with oesophageal cancer

N. Slim, Silvia Fabiano, Sarah E. Jensen, Ditte Sloth Møller et al.
4 citations
Acta Oncologica
Advanced Radiotherapy Techniques
7.53
article

Radiotherapy quality assurance in the PROTECT trial – a European randomised phase III-trial comparing proton and photon therapy in the treatment of patients with oesophageal cancer

N. Slim, Silvia Fabiano, Sarah E. Jensen, Ditte Sloth Møller, Christina T. Muijs, Richard Canters, Gloria Vilches‐Freixas, Muhammad Shamshad, F. Goudjil, Marie‐Claude Biston, Marie Lecornu, Camilla Skinnerup Byskov, Artūrs Meijers, Jessica Serrand, Valentina Vanoni, Pieter Populaire, Daniele Scartoni, Mai Lykkegaard Ehmsen, J. Doyen, Karin Haustermans, G. Créhange, Panagiotis Balermpas, Damien C. Weber, Sara Broggi, Gilles Defraene, Sebastian Makocki, Rebecca Bütof, Maria Fuglsang Jensen, Marianne Nordsmark, Antonio Maña, Lone Hoffmann, Ester M. Orlandi, Alfredo Mirandola, A. Martignano, Hanna Rahbek Mortensen, Anthony Vela, Diana A. Mitrea, Marie Vidal, Francesco Fracchiola
article en
4 citations

Abstract

A comprehensive RTQA programme was implemented for the PROTECT phase III trial. All centres adhered to guidelines for pre-trial QA. For on-trial QA, major variations were primarily seen for target delineations (< 30%), and no treatment plans required re-optimisation.

Acta OncologicaVol. 64
University Medical Center Groningen (NL), Proton (Malaysia) (MY), University of Groningen (NL), Aarhus University (DK), University of Pavia (IT), Maastricht University Medical Centre (NL), Helmholtz-Zentrum Dresden-Rossendorf (DE), Paul Scherrer Institute (CH), Aarhus University Hospital (DK), University Hospital of Zurich (CH), National Center for Oncological Hadrontherapy (IT), Centre Léon Bérard (FR), Centre François Baclesse (FR), OncoRay (DE), Centre Antoine Lacassagne (FR), MedAustron (AT), Maastro Clinic (NL), University Hospital Carl Gustav Carus (DE), Institut Curie (FR), KU Leuven (BE)
Openalex Percentile: Top 3%
Advanced Radiotherapy Techniques
7.53
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.